Avingtrans partners with IBEX to expand bone density testing through 3D x-ray technology

AVG

Avingtrans plc (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced that its medical imaging subsidiary, Adaptix Ltd, has signed a Memorandum of Understanding with IBEX Innovations Ltd to integrate IBEX’s CorteX bone health software into Adaptix’s FDA 510(k) cleared and CE marked Ortho 3D X-ray Imaging System (the Ortho350).

By integrating CorteX into the Ortho350 portable 3D X-ray imaging platform, the two companies aim to provide patients with a pay-per-scan bone density report at the point of care (“POC”), making bone density assessment widely available. Preliminary surveys indicated that this would be strongly welcomed by patients if offered on a cash-pay basis alongside other routine clinical assessments.

CorteX outputs the same recognised clinical biomarkers as dual-energy X-ray absorptiometry (“DXA”), with a low T-score at the wrist being an established indicator of elevated fracture risk and general bone loss, a key concern, particularly for women approaching the menopause. The CorteX software is FDA 510(k) submission pending and is not yet available for commercial distribution or sale in the United States.

The Ortho350 is a portable Digital Tomosynthesis system designed to provide high-resolution, low-dose 3D imaging for musculoskeletal diagnostics at the POC. The system addresses the limitations of traditional 2D X-ray imaging while offering a more accessible alternative to full CT scans.

Dr Paul Scott, Chief Executive Officer of IBEX, commented:

“Together we are bringing bone health assessment to the physician’s desktop. This is transformational for patients who often only become aware of a problem once a fracture has occurred. Making bone health assessment fast, easy and widely accessible is the missing ingredient to support clinicians in stopping osteoporosis in its tracks.”

Stuart Gall, Chief Executive Officer of the Medical and Industrial Imaging Division at Avingtrans, commented:

“We are excited to be taking this first step with IBEX and working with them to bring their excellent bone density test to market on the Ortho350 imaging platform. We have asked them to join our exhibition stand at RSNA 2026 in Chicago and would welcome any imaging centres, hospitals or interested OEMs to visit us on Stand 3159, South Hall, Level 3.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Avingtrans partners with IBEX to expand bone density testing through 3D x-ray technology

Avingtrans subsidiary Adaptix has partnered with IBEX Innovations to integrate its CorteX bone health software into the Ortho350 imaging...

Avingtrans CEO Steve McQuillan on record revenue, nuclear demand and medical imaging progress

Avingtrans plc (LON: AVG) CEO Steve McQuillan discusses record revenue of £163 million, adjusted EBITDA exceeding £20 million, a...

Avingtrans plc: Record £163m Revenue, 90% Order Cover and Adaptix Nears Commercial Breakthrough

Avingtrans CEO Steve McQuillan discusses record £163m revenue, more than 90% order coverage and growing nuclear opportunities, while Adaptix...

Avingtrans reports record revenue and strong profit growth as AI and nuclear demand builds

Avingtrans reported record revenue of £163.3m for FY2026, with adjusted EBITDA rising 24% to £20.7m as strong demand across...

Avingtrans acquires US nuclear specialist Joseph Oat for $2.5m

Avingtrans has acquired the intellectual property, trading history and brand of US nuclear engineering specialist Joseph Oat for $2.5m,...

Adaptix expands US distribution with Digital X-Ray Technologies partnership

Adaptix has appointed Digital X-Ray Technologies as a US distributor for the Ortho350, expanding access to its 3D orthopaedic...

Search